Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00384865
Other study ID # 458
Secondary ID R01HL082895-01
Status Terminated
Phase Phase 2
First received September 30, 2006
Last updated July 18, 2017
Start date September 2006
Est. completion date October 2009

Study information

Verified date July 2017
Source University of Pennsylvania
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether aspirin and simvastatin are safe and effective for the treatment of pulmonary arterial hypertension (PAH).


Description:

PAH is characterized by dyspnea, fatigue, and lower extremity edema as a result of heart failure. In PAH, in situ thrombosis may occur in the lungs, and pulmonary endothelial dysfunction is well-recognized. As aspirin inhibits platelet aggregation, there may be value in using aspirin to treat PAH. Simvastatin has beneficial effects on blood vessels in other types of cardiovascular disease. Therefore, simvastatin may similarly benefit patients with PAH.

Participants in this study will be randomly assigned to receive 6 months of daily placebo tablets, daily aspirin and daily placebo, daily simvastatin and daily placebo, or daily aspirin and daily simvastatin in a double-blind fashion. The study will compare the safety and efficacy of aspirin to placebo and simvastatin to placebo.


Recruitment information / eligibility

Status Terminated
Enrollment 64
Est. completion date October 2009
Est. primary completion date October 2009
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Mean pulmonary artery pressure greater than 25 mm Hg at rest with a pulmonary capillary wedge pressure less than 16 mm Hg

- Diagnosis of PAH that is a) idiopathic, b) familial, or c) associated with collagen vascular disease, HIV infection, congenital systemic-to-pulmonary shunt, or former anorexigen use

- Most recent pulmonary function tests showing FEV1/FVC ratio greater than 50% AND one of the following conditions: a) total lung capacity greater than 70% predicted, or b) total lung capacity between 60% and 70% of predicted value with no more than mild patchy interstitial lung disease on high resolution computerized tomography of the chest

- Ability to perform six-minute walk testing without limitations in musculoskeletal function or coordination

- Negative pregnancy test at screening visit for women of childbearing potential

- If female, willing to use adequate form of birth control

Exclusion Criteria:

- PAH related to other etiologies

- Diagnosis of sickle cell disease

- Clinically significant untreated sleep apnea, as diagnosed by polysomnography

- Left-sided valvular disease (more than moderate mitral valve stenosis or insufficiency or aortic stenosis or insufficiency), pulmonary artery or valve stenosis, or ejection fraction less than 45% on echocardiography

- Hospitalized or acutely ill

- Kidney failure

- Initiation of PAH therapy (prostacyclin analogues, endothelin [ET]-1 receptor antagonists, phosphodiesterase [PDE]-5 inhibitors) within 3 months of study entry

- Allergy or hypersensitivity to aspirin or simvastatin

- Absolute indication for aspirin or other anti-platelet therapy

- Current treatment with statin therapy

- Inability or unwillingness to avoid non-steroidal, anti-inflammatory medications for 6 months following study entry

- Current or recent use or planned treatment with one of the following: amiodarone, cyclosporine, itraconazole, ketoconazole, erythromycin, clarithromycin, HIV protease inhibitors, nefazodone, cimetidine, danazol, large quantities of grapefruit juice (more than 1 quart daily), verapamil, fibrates, or niacin

- Peptic or duodenal ulcer diagnosed within 1 year of study entry

- Gastrointestinal bleeding within 6 months prior of study entry

- Bleeding diathesis

- History of intracranial bleeding

- Anemia (hematocrit less than 30%) at screening

- International normalized ratio (INR) greater than 3.0 at screening

- Severe thrombocytopenia (less than 75,000/L) at screening

- Hepatic transaminases greater than twice the upper limit of normal at screening

- Chronic liver disease (e.g., cirrhosis, chronic hepatitis) with portal hypertension

- Current or recent (within 6 months of study entry) chronic heavy alcohol consumption

- History of myositis

- Creatine phosphokinase (CPK) greater than 1.5 times the upper limit of normal at screening

- Abnormalities of the arm or hand or past radical mastectomy that might prevent brachial artery ultrasound

- Pregnant or breastfeeding

- Current use of another investigational drug for PAH

- Received a lung transplant

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Simvastatin
Simvastatin 40 mg, taken orally, once a day for 6 months
Aspirin
Aspirin 81 mg, taken orally, once a day for 6 months
Placebo
Placebo, taken orally, once a day for 6 months

Locations

Country Name City State
United States Johns Hopkins University Baltimore Maryland
United States Tufts University School of Medicine Boston Massachusetts
United States Columbia University New York New York
United States University of Pennsylvania Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
University of Pennsylvania National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Kawut SM, Bagiella E, Lederer DJ, Shimbo D, Horn EM, Roberts KE, Hill NS, Barr RG, Rosenzweig EB, Post W, Tracy RP, Palevsky HI, Hassoun PM, Girgis RE; ASA-STAT Study Group. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hyper — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Distance Walked in Six Minutes Measured at 6 months
Secondary Time to Clinical Worsening Events (Number of Events) Defined by the addition of new PAH therapies or dose increases in previously stable PAH therapy, hospitalization for right-sided heart failure, lung transplantation, atrial septostomy, and cardiovascular and all-cause death. Measured at 6 months
Secondary Adverse Events Please refer to the Adverse Event Tables for specific information Measured at 6 months
See also
  Status Clinical Trial Phase
Completed NCT04095286 - Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants Phase 1
Enrolling by invitation NCT03683186 - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Phase 3
Completed NCT02191137 - Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION) Phase 4
Completed NCT01959828 - Confirmatory Study of IK-3001 in Japanese Subjects With Peri-/Post-op Pulmonary Hypertension Assoc. With Cardiac Surgery Phase 3
Withdrawn NCT01202045 - Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients N/A
Completed NCT00963027 - Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil Phase 1
Completed NCT01121458 - Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed Phase 4
Completed NCT00963001 - Effect of Food on the Pharmacokinetics of Oral Treprostinil Phase 1
Terminated NCT00825266 - Insulin Resistance in Pulmonary Arterial Hypertension Phase 4
Active, not recruiting NCT03926572 - Acute Decompensation of Pulmonary Hypertension N/A
Completed NCT02826252 - Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20) N/A
Completed NCT02545465 - A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice N/A
Recruiting NCT04498299 - Stress Echocardiography in Patients Recovery From Mild COVID-19 Illness
Recruiting NCT02558582 - Effect of Exercise Training in Patients With Pulmonary Hypertension N/A
Active, not recruiting NCT02562235 - Riociguat in Children With Pulmonary Arterial Hypertension (PAH) Phase 3
Completed NCT02755298 - Chronic Clinical Effect of Acetazolamide Phase 2/Phase 3
Completed NCT02576002 - Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension) N/A
Terminated NCT03043976 - Using Step Count to Enhance Daily Physical Activity in Pulmonary Hypertension N/A
Completed NCT01317134 - Endothelial Function in Patients With Pulmonary Arterial Hypertension N/A
Completed NCT01178073 - A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) Phase 3